[1] Voeltz GK, Rolls MM, Rapoport TA. Structural organization of the endoplasmic reticulum. EMBO Rep, 2002, 3:944-950.
[2] González-Quiroz M, Blondel A, Sagredo A, et al. When endoplasmic reticulum proteostasis meets the DNA damage response. Trends Cell Bio, 2020, 30:881-891.
[3] Baiceanu A, Mesdom P, Lagouge M, et al. Endoplasmic reticulum proteostasis in hepatic steatosis. Nat Rev Endocrinol, 2016, 12:710-722.
[4] Hetz C, Martinon F, Rodriguez D, et al. The unfolded protein response: integrating stress signals through the stress sensor IRE1α. Physiol Rev, 2011, 91:1219-1243.
[5] Xia SW, Wang ZM, Sun SM, et al. Endoplasmic reticulum stress and protein degradation in chronic liver disease. Pharmacol Res, 2020, 161:105218.
[6] Lee KP, Dey M, Neculai D, et al. Structure of the dual enzyme Ire1 reveals the basis for catalysis and regulation in nonconventional RNA splicing. Cell, 2008, 132:89-100.
[7] Maiers JL, Malhi H. Endoplasmic reticulum stress in metabolic liver diseases and hepatic fibrosis. Semin Liver Dis, 2019, 39:235-248.
[8] Moncan M, Mnich K, Blomme A, et al. Regulation of lipid metabolism by the unfolded protein response. J Cell Mol Med, 2021, 25:1359-1370.
[9] Karagöz GE, Aragón T, Acosta-Alvear D. Recent advances in signal integration mechanisms in the unfolded protein response. F1000Res, 2019, 8:F1000 Faculty Rev-1840.
[10] Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. Nat Rev Mol Cell Biol, 2020, 21:421-438.
[11] Bommiasamy H, Back SH, Fagone P, et al. ATF6alpha induces XBP1-independent expansion of the endoplasmic reticulum. J Cell sci, 2009, 122:1626-1636.
[12] Sarvani C, Sireesh D, Ramkumar KM. Unraveling the role of ER stress inhibitors in the context of metabolic diseases. Pharmacol Res, 2017, 119:412-421.
[13] Song MJ, Malhi H. The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease. Pharmacol Ther, 2019, 203:107401.
[14] Lebeaupin C, Vallée D, Hazari Y, et al. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J hepatol, 2018, 69:927-947.
[15] Metcalf MG, Higuchi-Sanabria R, Garcia G, et al. Beyond the cell factory: homeostatic regulation of and by the UPR(ER). Sci Adv, 2020, 6:eabb9614.
[16] Zhang K, Wang S, Malhotra J, et al. The unfolded protein response transducer IRE1α prevents ER stress-induced hepatic steatosis. EMBO J, 2011, 30:1357-1375.
[17] Wang S, Chen Z, Lam V, et al. IRE1α-XBP1s induces PDI expression to increase MTP activity for hepatic VLDL assembly and lipid homeostasis. Cell Metab, 2012, 16:473-486.
[18] Lee AH, Scapa EF, Cohen DE, et al. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science, 2008, 320:1492-1496.
[19] So JS, Hur KY, Tarrio M, et al. Silencing of lipid metabolism genes through IRE1α-mediated mRNA decay lowers plasma lipids in mice. Cell Metab, 2012, 16:487-499.
[20] Lebeaupin C, Vallée D, Rousseau D, et al. Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice. Hepatology, 2018, 68:515-532.
[21] Lauressergues E, Bert E, Duriez P, et al. Does endoplasmic reticulum stress participate in APD-induced hepatic metabolic dysregulation? Neuropharmacology, 2012, 62:784-796.
[22] Oyadomari S, Harding HP, Zhang Y, et al. Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice. Cell Metab, 2008, 7:520-532.
[23] Xiao G, Zhang T, Yu S, et al. ATF4 protein deficiency protects against high fructose-induced hypertriglyceridemia in mice. J Biol Chem, 2013, 288:25350-25361.
[24] Jo H, Choe SS, Shin KC, et al. Endoplasmic reticulum stress induces hepatic steatosis via increased expression of the hepatic very low-density lipoprotein receptor. Hepatology, 2013, 57:1366-1377.
[25] Wang Y, Zhang L, Wu X, et al. The role of CCAAT enhancer-binding protein homologous protein in human immunodeficiency virus protease-inhibitor-induced hepatic lipotoxicity in mice. Hepatology, 2013, 57:1005-1016.
[26] Chen X, Zhang F, Gong Q, et al. Hepatic ATF6 increases fatty acid oxidation to attenuate hepatic steatosis in mice through peroxisome proliferator-activated receptor α. Diabetes, 2016, 65:1904-1915.
[27] Usui M, Yamaguchi S, Tanji Y, et al. Atf6alpha-null mice are glucose intolerant due to pancreatic beta-cell failure on a high-fat diet but partially resistant to diet-induced insulin resistance. Metabolism, 2012, 61:1118-1128.
[28] Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science, 2004, 306:457-461.
[29] Rennert C, Heil T, Schicht G, et al. Prolonged lipid accumulation in cultured primary human hepatocytes rather leads to ER stress than oxidative stress. Int J Mol Sci, 2020, 21.
[30] Zelber-Sagi S, Godos J, Salomone F. Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. Therap Adv Gastroenterol, 2016, 9:392-407.
[31] Jiang S, Yan C, Fang QC, et al. Fibroblast growth factor 21 is regulated by the IRE1α-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J Biol Chem, 2014, 289:29751-29765.
[32] Wang M, Kaufman RJ. Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature, 2016, 529:326-335.
[33] Leuschner UF, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology, 2010, 52:472-479.
[34] Han KL, Choi JS, Lee JY, et al. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes. Diabetes, 2008, 57:737-745. |
